{"id":492992,"date":"2021-05-13T08:18:17","date_gmt":"2021-05-13T12:18:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/"},"modified":"2021-05-13T08:18:17","modified_gmt":"2021-05-13T12:18:17","slug":"silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/","title":{"rendered":"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review."},"content":{"rendered":"
\n

Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its \u00a0investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review \u00a0in the Netherlands. \u00a0\u00a0Eric Weisblum, CEO of Silo Pharma stated \u201cWe are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders.\u201d<\/p>\n

\n \u00a0About Silo Pharma<\/strong>\n <\/p>\n

Silo Pharma. Inc. is a development stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders. Silo\u2019s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit \u00a0www.silopharma.com<\/u><\/a><\/p>\n

\n Safe Harbor and Forward-Looking Statements<\/strong>\n <\/p>\n

This news release contains “forward-looking statements” within the meaning of the \u201csafe-harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n

Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com<\/u><\/a><\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its \u00a0investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review \u00a0in the Netherlands. \u00a0\u00a0Eric Weisblum, CEO of Silo Pharma stated \u201cWe are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders.\u201d \u00a0About Silo Pharma Silo Pharma. Inc. is a development stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders. Silo\u2019s mission … <\/p>\n

Continue reading “Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review.”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-492992","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSilo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its \u00a0investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review \u00a0in the Netherlands. \u00a0\u00a0Eric Weisblum, CEO of Silo Pharma stated \u201cWe are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders.\u201d \u00a0About Silo Pharma Silo Pharma. Inc. is a development stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders. Silo\u2019s mission … Continue reading "Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review."\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-13T12:18:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review.\",\"datePublished\":\"2021-05-13T12:18:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/\"},\"wordCount\":398,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/\",\"name\":\"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==\",\"datePublished\":\"2021-05-13T12:18:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review. - Market Newsdesk","og_description":"Englewood Cliffs, NJ, May 13, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a development stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that its \u00a0investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review \u00a0in the Netherlands. \u00a0\u00a0Eric Weisblum, CEO of Silo Pharma stated \u201cWe are pleased to have reached this milestone and look forward to sharing further information on this study with the scientific community and our shareholders.\u201d \u00a0About Silo Pharma Silo Pharma. Inc. is a development stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson\u2019s, and other rare neurological disorders. Silo\u2019s mission … Continue reading \"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-13T12:18:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review.","datePublished":"2021-05-13T12:18:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/"},"wordCount":398,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/","name":"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==","datePublished":"2021-05-13T12:18:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIzNTU1MiM0MTgxNjUxIzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-announces-important-milestone-investigator-led-study-using-psilocybin-to-treat-parkinsons-disease-has-been-submitted-for-ethics-board-review\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma announces important milestone. Investigator led study using Psilocybin to treat Parkinson\u2019s disease has been submitted for ethics board review."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/492992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=492992"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/492992\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=492992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=492992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=492992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}